Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered With the Optejet

GlobeNewswire10/23 19:00

Evenovia Shares Are Trading Higher After the Company Announced It Will Present Results From Its Successful Phase 3 CPN-302 Study of Clobetasol Propionate Suspension 0.05% as a Treatment for Inflammation and Pain Following Ocular Surgery. The Results...

Benzinga10/17 02:03

Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

GlobeNewswire10/16 19:00

Eyenovia Announces Commencement of Manufacturing of Its Advanced, Second Generation Optejet Device

GlobeNewswire10/01 19:00

12 Health Care Stocks Moving In Friday's After-Market Session

Benzinga09/28 04:31

Eyenovia Stock Slides on Pricing Capital Raise of About $4 Million via Securities Offering

Seeking Alpha09/27 20:54